XHKG1228
Market cap8mUSD
Dec 23, Last price
0.15HKD
1D
2.04%
1Q
-48.28%
IPO
-98.31%
Name
Canbridge Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
0.58
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
103m
+30.26%
Net income
-379m
L-21.64%
CFO
-278m
L-0.98%
Profile
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Caphosol Mouth Rinse for temporary and persistent dryness of the mouth and throat. It also engages in the development of CAN008, an artificially engineered antibody-like fully human fusion protein for the treatment of glioblastoma multiforme; CAN108, an orally absorbed reversible inhibitor of the ileal bile acid transporter to treat rare cholestatic liver diseases; CAN106, a humanized monoclonal antibody against complement C5 being developed for the treatment of complement-mediated diseases; CAN103, a recombinant human enzyme replacement therapy (ERT); CAN104, a recombinant human ERT; CAN105, a bispecific antibody; CAN201, a gene therapy program that utilizes adeno-associated virus (AAV) sL65 capsid; and CAN202, a gene therapy program utilizing AAV sL65 capsid. The company was founded in 2012 and is headquartered in Beijing, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 102,871 30.26% | 78,972 153.43% | 31,161 158.98% | ||
Cost of revenue | 469,418 | 536,941 | 686,308 | ||
Unusual Expense (Income) | |||||
NOPBT | (366,547) | (457,969) | (655,147) | ||
NOPBT Margin | |||||
Operating Taxes | 21,750 | 15,469 | |||
Tax Rate | |||||
NOPAT | (366,547) | (479,719) | (670,616) | ||
Net income | (378,837) -21.64% | (483,475) -55.11% | (1,077,006) 27.30% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 76 | 34 | 563,804 | ||
BB yield | |||||
| Debt | |||||
Debt current | 34,724 | 39,895 | 38,750 | ||
Long-term debt | 218,819 | 233,019 | 34,584 | ||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | 116,052 | (178,243) | (672,481) | ||
| Cash flow | |||||
Cash from operating activities | (278,231) | (280,979) | (587,070) | ||
CAPEX | (5,144) | (34,786) | (5,332) | ||
Cash from investing activities | (26,855) | (34,786) | 126,094 | ||
Cash from financing activities | (28,017) | (20,704) | 854,310 | ||
FCF | (269,079) | (575,772) | (684,588) | ||
| Balance | |||||
Cash | 137,491 | 451,157 | 745,815 | ||
Long term investments | |||||
Excess cash | 132,347 | 447,208 | 744,257 | ||
Stockholders' equity | (3,789,414) | (3,162,701) | (2,777,216) | ||
Invested Capital | 3,891,555 | 3,625,154 | 3,521,231 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 424,379 | 424,211 | 94,241 | ||
Price | |||||
Market cap | |||||
EV | |||||
EBITDA | (338,087) | (435,991) | (639,441) | ||
EV/EBITDA | |||||
Interest | 8,948 | 6,863 | 3,079 | ||
Interest/NOPBT | |||||